Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesDermatologyHealth Net Hyperhidrosis Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP.MP.62

    Hyperhidrosis Treatments

    Customize your policy alerts

    Sign up for Health Net Policy CP.MP.62 alerts

    Get alerted when Policy CP.MP.62 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria for iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy (ETS) for primary hyperhidrosis for Health Net/Centene-affiliated health plans and affected members/enrollees and providers.

    Policy Summary
    PayerHealth Net
    PolicyHyperhidrosis Treatments
    Policy CodePolicy CP.MP.62
    Change TypeMaterial revisions to criteria and thresholds
    Effective Date
    Last ReviewOct 13, 2025
    Next Review Date
    Key ActionObtain prior authorization and document failed conservative therapy (iontophoresis or botulinum toxin) before surgical excision or ETS.
    SourceLink
    POLICY UPDATE CHANGES

    Updated criteria I.E.3. by removing (hyperhidrosis often improves pregnancy) and added epilepsy to contraindications.

    Updated Criteria II.B. to greater than 55 beats per minute (resting heart rate).

    Added counseling requirement on risks of procedure for ETS candidacy (Criteria III.I).

    Removed six-month time frame requirement for trial of conservative management and removed certain prior pharmacotherapy trial language.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Covered procedures
    >55 bpmETS resting HR threshold
    5Iontophoresis contraindications
    1Insufficient-evidence treatments

    Coverage Criteria

    I. Iontophoresis (medically necessary)

    Covered when ALL of the following are met:

    Iontophoresis criteria: Diagnosis of primary hyperhidrosis; development of medical complications (e.g., skin maceration with secondary skin infections) or significant constant disruption of professional and/or social life due to excessive sweating; failed a trial of conservative management including adherent application of aluminum chloride hexahydrate (prescription Drysol) or topical agents resulted in a severe rash; and absence of the following contraindications: cardiac pacemaker; cardiac arrhythmias; pregnancy; metal implants (depending on size and position); and epilepsy.

    From Policy/Criteria I.A through I.D

    II. Surgical excision of axillary sweat glands (medically necessary)

    Covered when ALL of the following are met:

    Axillary excision criteria: Meets all iontophoresis criteria I.A through I.D; has persistent and severe primary hyperhidrosis; and has failed one of the following: 1) iontophoresis or 2) trial of botulinum toxin.

    From Policy/Criteria II.A through II.C

    III. Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis (medically necessary)

    Covered when ALL of the following are met:

    ETS criteria: Meets all iontophoresis criteria I.A through I.D; resting heart rate > 55 beats per minute; hyperhidrosis symptoms began at an early age (usually <16 years) and surgery is requested for a young member (usually <25 years); body mass index < 28; reports no sweating during sleep; has no significant comorbidities; has persistent and severe primary hyperhidrosis; has failed one of the following: 1) iontophoresis or 2) trial of botulinum toxin (for predominantly axillary hyperhidrosis); and member has been counseled on risks of the procedure.resting heart rate >55 bpm; BMI <28; age considerations

    From Policy/Criteria III.A through III.I and revision notes adding counseling requirement and heart rate/BMI thresholds

    IV. Other treatments

    Insufficient evidence treatments: There is insufficient published peer-reviewed evidence to support other treatments for hyperhidrosis, including but not limited to microwave therapy or liposuction as the sole method of removing axillary sweat glands.

    Policy IV

    The policy does not support microwave therapy or liposuction when used as the sole method to remove axillary sweat glands. The document states there is insufficient published peer‑reviewed evidence to support these and similar treatments for hyperhidrosis, and specifically calls out microwave therapy and liposuction as examples of unsupported approaches. The miraDry System is FDA‑cleared for primary axillary hyperhidrosis but national guidance (NICE) characterizes current evidence for transcutaneous microwave ablation as inadequate in quantity and quality and recommends its use only with special governance, consent, audit, or research arrangements.

    All treatments for hyperhidrosis that lack sufficient peer‑reviewed evidence are considered unsupported by this policy. Examples explicitly included are diathermy/microwave modalities and liposuction performed alone for axillary sweat gland removal. The policy emphasizes the insufficiency of published evidence for these approaches and references regulatory and health‑technology guidance noting limited or inadequate data to establish safety and efficacy.

    Coding

    Referenced CPT CodesCPT
    11450Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair
    11451Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair
    15877Suction assisted lipectomy; trunk
    15878Suction assisted lipectomy; upper extremity
    32664Thoracoscopy, surgical; with thoracic sympathectomy
    97024Application of a modality to 1 or more areas; diathermy (eg, microwave)
    97033Application of a modality to 1 or more areas; iontophoresis, each 15 minutes
    inv-08: Resting heart rate — ETS candidacy
    Resting heart rate threshold> 55 beats per minute
    ContextRequired for ETS candidacy in addition to meeting iontophoresis criteria and other ETS-specific criteria
    Documentation neededMedical record must document measured resting heart rate exceeding 55 bpm as part of prior authorization/assessment
    inv-09: Body mass index (BMI) — criterion
    BMI threshold< 28
    Role in ETS candidacyMember must have BMI less than 28 as one of the ETS eligibility criteria
    Documentation needed

    Provider Actions & Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required per plan for procedures referenced by CPT codes when applicable. Providers should obtain authorization before scheduling or performing procedures such as iontophoresis (CPT 97033), thoracoscopic sympathectomy (CPT 32664), excision of axillary sweat glands or related excision codes (e.g., 11450, 11451), and other listed procedures. Inclusion of CPT codes here is informational; verify plan-specific authorization rules and use the most current coding guidance when submitting claims.

    • Affected CPT codes include: 97033 (iontophoresis), 32664 (thoracoscopic sympathectomy/ETS), 11450, 11451 (axillary excision codes), and related procedure codes listed in the policy coding section.
    • Authorization must be obtained per member's benefit plan prior to service.
    Prior Authorization

    Prior Therapies Required Before Surgical Excision or ETS

    Before surgical axillary excision or endoscopic thoracic sympathectomy (ETS) is approved, documentation must show the member failed at least one prior non‑surgical therapy: either a trial of iontophoresis (per I. criteria) or a trial of botulinum toxin (per policy criteria). Requests lacking evidence of these prior therapies are subject to denial.

    Definitions

    inv-15: Primary hyperhidrosis — diagnostic features
    DefinitionVisible, excessive sweating of at least six months' duration without apparent cause
    Typical locationsOften focal — axillary (underarms), palmar (hands), or plantar (feet)
    Provoking factorsInduced by sympathetic hyperactivity and often triggered by emotional stimuli
    Clinical impactCan cause emotional distress, ruin clothing, and lead to occupational disability
    inv-16: Secondary hyperhidrosis — diagnostic features
    DefinitionExcessive sweating attributable to medications or underlying medical conditions

    Background

    Primary focal hyperhidrosis is an idiopathic condition characterized by visible, excessive sweating beyond physiological needs and is commonly localized to the axillae, palms, or soles. It is defined in the literature as persistent for at least six months without an apparent secondary cause and is thought to result from sympathetic hyperactivity. The condition frequently produces substantial emotional, social, or occupational impairment and is distinct from secondary hyperhidrosis, which is typically generalized or craniofacial and related to medications or underlying medical disorders.

    Policy Summary
    PayerHealth Net
    PolicyHyperhidrosis Treatments
    Policy CodePolicy CP.MP.62
    Change TypeMaterial revisions to criteria and thresholds
    Effective Date
    Last ReviewOct 13, 2025
    Next Review Date
    Key ActionObtain prior authorization and document failed conservative therapy (iontophoresis or botulinum toxin) before surgical excision or ETS.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & AuthorizationDefinitionsBackground
    Body mass index must be recorded in the medical record for prior authorization
    • One of the following must be documented prior to approval for axillary excision or ETS: iontophoresis OR trial of botulinum toxin.
    • If prior therapies were contraindicated or not feasible, clinical rationale and supporting documentation must be provided.
    Denial Risk

    Requests Not Meeting Criteria Are Subject to Denial

    Requests for iontophoresis, axillary excision, or ETS that do not meet the medical necessity criteria are subject to denial. Denial risk is increased when required documentation is missing, prior therapies have not been attempted when indicated, or contraindications are present.

    • Denial risks include: missing documentation of primary hyperhidrosis diagnosis, absence of medical complications or significant functional disruption, no record of prior conservative therapy (e.g., aluminum chloride) for iontophoresis requests, or no trial of iontophoresis/botulinum toxin for surgical requests.
    • Verify contraindications (e.g., pacemaker, arrhythmia, pregnancy, epilepsy, certain metal implants) prior to submitting request.
    Documentation Required

    Required Documentation Elements

    Documentation submitted with prior authorization requests should clearly demonstrate: diagnosis of primary hyperhidrosis; presence of medical complications (for example, skin maceration with secondary infection) or significant constant disruption of professional/social life due to sweating; details of conservative management tried (including adherence to aluminum chloride hexahydrate/Drysol or reason for intolerance); results of iontophoresis or botulinum toxin trials when applicable; and absence of contraindications. Include clinical notes, treatment dates, response to therapies, and counseling about surgical risks when surgery is requested.

    • Document primary hyperhidrosis diagnosis and symptom onset.
    • Document medical complications or significant functional impairment attributable to sweating.
    • Provide evidence of conservative management and trial dates (topical aluminum chloride, iontophoresis, botulinum toxin) and outcomes.
    • State any contraindications (pacemaker, arrhythmias, pregnancy, metal implants, epilepsy) or rationale if treatments were not tried.
    • For ETS requests, include counseling that the member was informed of procedure risks.
    Typical distribution
    Usually generalized or craniofacial rather than focal
    Common causesDrugs (e.g., tricyclic antidepressants, SSRIs) or diseases (e.g., febrile illnesses, diabetes, menopause)
    Management implicationTreatment should focus on addressing the underlying cause rather than focal therapies